BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16778106)

  • 1. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
    Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
    Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
    Takimoto CH; Morrison G; Harold N; Quinn M; Monahan BP; Band RA; Cottrell J; Guemei A; Llorens V; Hehman H; Ismail AS; Flemming D; Gosky DM; Hirota H; Berger SJ; Berger NA; Chen AP; Shapiro JD; Arbuck SG; Wright J; Hamilton JM; Allegra CJ; Grem JL
    J Clin Oncol; 2000 Feb; 18(3):659-67. PubMed ID: 10653882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
    Raymond E; Boige V; Faivre S; Sanderink GJ; Rixe O; Vernillet L; Jacques C; Gatineau M; Ducreux M; Armand JP
    J Clin Oncol; 2002 Nov; 20(21):4303-12. PubMed ID: 12409328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
    Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
    Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
    Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
    Venook AP; Enders Klein C; Fleming G; Hollis D; Leichman CG; Hohl R; Byrd J; Budman D; Villalona M; Marshall J; Rosner GL; Ramirez J; Kastrissios H; Ratain MJ
    Ann Oncol; 2003 Dec; 14(12):1783-90. PubMed ID: 14630685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
    J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
    Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
    Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
    Marier JF; Pheng L; Trinh MM; Burris HA; Jones S; Anderson K; Warner S; Porubek D
    J Pharm Sci; 2011 Oct; 100(10):4536-45. PubMed ID: 21630281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
    Kuppens IE; Dansin E; Boot H; Feger C; Assadourian S; Bonneterre ME; Beijnen JH; Schellens JH; Bonneterre J
    Clin Cancer Res; 2006 Jun; 12(12):3774-81. PubMed ID: 16778105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
    Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.